Company profile NVCT
After 38 days of this quarter the interest is at 20.0. Based on that we can calculate that during remaining 53 days it will total up to 48.0. Nuvectis Pharma expected interest is significantly higher compared to same quarter last year (+92.0%) but lower than previous quarter (-72.9%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 171 | 82 -52.0% QoQ | 0 -100.0% QoQ | 37 inf% QoQ |
| 2020 | 78 -54.4% YoY 110.8% QoQ | 158 92.7% YoY 102.6% QoQ | 42 inf% YoY -73.4% QoQ | 38 2.7% YoY -9.5% QoQ |
| 2021 | 102 30.8% YoY 168.4% QoQ | 102 -35.4% YoY 0.0% QoQ | 164 290.5% YoY 60.8% QoQ | 126 231.6% YoY -23.2% QoQ |
| 2022 | 160 56.9% YoY 27.0% QoQ | 48 -52.9% YoY -70.0% QoQ | 145 -11.6% YoY 202.1% QoQ | 34 -73.0% YoY -76.6% QoQ |
| 2023 | 25 -84.4% YoY -26.5% QoQ | 87 81.2% YoY 248.0% QoQ | 176 21.4% YoY 102.3% QoQ | 177 420.6% YoY 0.6% QoQ |
| 2024 | 20 -20.0% YoY -88.7% QoQ | - | - | - |
The average 5 years interest of Nuvectis Pharma was 7.56 per week. The last year interest of Nuvectis Pharma compared to the last 5 years has changed by 23.41%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 48.33%.
There is not enough data for Nuvectis Pharma login to provide analysis
There is not enough data for Nuvectis Pharma login to provide correlation calculation
There is not enough data for Nuvectis Pharma login to provide analysis
There is not enough data for NXP800 heat shock factor inhibitor to provide analysis
There is not enough data for NXP800 heat shock factor inhibitor to provide correlation calculation
There is not enough data for NXP800 heat shock factor inhibitor to provide analysis
There is not enough data for NXP900 c-Src and YES1 kinase inhibitor to provide analysis
There is not enough data for NXP900 c-Src and YES1 kinase inhibitor to provide correlation calculation
There is not enough data for NXP900 c-Src and YES1 kinase inhibitor to provide analysis
After 38 days of this quarter the interest is at 147.0. Based on that we can calculate that during remaining 53 days it will total up to 352.0. precision medicines expected interest is significantly higher compared to previous quarter (+47.3%) and same quarter last year (+72.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 29 | 58 100.0% QoQ | 20 -65.5% QoQ | 115 475.0% QoQ |
| 2020 | 189 551.7% YoY 64.3% QoQ | 113 94.8% YoY -40.2% QoQ | 106 430.0% YoY -6.2% QoQ | 372 223.5% YoY 250.9% QoQ |
| 2021 | 158 -16.4% YoY -57.5% QoQ | 134 18.6% YoY -15.2% QoQ | 210 98.1% YoY 56.7% QoQ | 186 -50.0% YoY -11.4% QoQ |
| 2022 | 274 73.4% YoY 47.3% QoQ | 353 163.4% YoY 28.8% QoQ | 194 -7.6% YoY -45.0% QoQ | 225 21.0% YoY 16.0% QoQ |
| 2023 | 204 -25.5% YoY -9.3% QoQ | 220 -37.7% YoY 7.8% QoQ | 241 24.2% YoY 9.5% QoQ | 239 6.2% YoY -0.8% QoQ |
| 2024 | 147 -27.9% YoY -38.5% QoQ | - | - | - |
The average 5 years interest of precision medicines was 14.51 per week. The last year interest of precision medicines compared to the last 5 years has changed by 27.91%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 205.26%.
After 39 days of this quarter the interest is at 389.0. Based on that we can calculate that during remaining 52 days it will total up to 908.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 526 | 813 54.6% QoQ | 847 4.2% QoQ | 804 -5.1% QoQ |
| 2020 | 871 65.6% YoY 8.3% QoQ | 691 -15.0% YoY -20.7% QoQ | 802 -5.3% YoY 16.1% QoQ | 716 -10.9% YoY -10.7% QoQ |
| 2021 | 839 -3.7% YoY 17.2% QoQ | 841 21.7% YoY 0.2% QoQ | 908 13.2% YoY 8.0% QoQ | 836 16.8% YoY -7.9% QoQ |
| 2022 | 942 12.3% YoY 12.7% QoQ | 891 5.9% YoY -5.4% QoQ | 935 3.0% YoY 4.9% QoQ | 859 2.8% YoY -8.1% QoQ |
| 2023 | 1009 7.1% YoY 17.5% QoQ | 969 8.8% YoY -4.0% QoQ | 991 6.0% YoY 2.3% QoQ | 941 9.5% YoY -5.0% QoQ |
| 2024 | 389 -61.4% YoY -58.7% QoQ | - | - | - |
The average 5 years interest of oncology was 66.74 per week. The last year interest of oncology compared to the last 5 years has changed by 10.88%. The interest for oncology is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by 13.58%.
After 34 days of this quarter the interest is at 14.0. Based on that we can calculate that during remaining 58 days it will total up to 38.0. biopharmaceutical company expected interest is significantly lower compared to previous quarter (-57.8%) and same quarter last year (-72.5%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 127 |
| 2019 | 118 -7.1% QoQ | 78 -33.9% QoQ | 153 96.2% QoQ | 205 61.4% YoY 34.0% QoQ |
| 2020 | 101 -14.4% YoY -50.7% QoQ | 226 189.7% YoY 123.8% QoQ | 71 -53.6% YoY -68.6% QoQ | 38 -81.5% YoY -46.5% QoQ |
| 2021 | 84 -16.8% YoY 121.1% QoQ | 188 -16.8% YoY 123.8% QoQ | 58 -18.3% YoY -69.1% QoQ | 87 128.9% YoY 50.0% QoQ |
| 2022 | 170 102.4% YoY 95.4% QoQ | 75 -60.1% YoY -55.9% QoQ | 134 131.0% YoY 78.7% QoQ | 138 58.6% YoY 3.0% QoQ |
| 2023 | 118 -30.6% YoY -14.5% QoQ | 54 -28.0% YoY -54.2% QoQ | 90 -32.8% YoY 66.7% QoQ | 14 -89.9% YoY -84.4% QoQ |
The average 5 years interest of biopharmaceutical company was 8.92 per week. The last year interest of biopharmaceutical company compared to the last 5 years has changed by -26.91%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -43.79%.
There is not enough data for serious unmet medical needs to provide analysis
There is not enough data for serious unmet medical needs to provide correlation calculation
There is not enough data for serious unmet medical needs to provide analysis
After 38 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 53 days it will total up to 0.0. Nuvectis Pharma stock expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 40 inf% QoQ | 102 155.0% QoQ | 147 44.1% QoQ |
| 2020 | 145 inf% YoY -1.4% QoQ | 48 20.0% YoY -66.9% QoQ | 0 -100.0% YoY -100.0% QoQ | 69 -53.1% YoY inf% QoQ |
| 2021 | 117 -19.3% YoY 69.6% QoQ | 76 58.3% YoY -35.0% QoQ | 34 inf% YoY -55.3% QoQ | 87 26.1% YoY 155.9% QoQ |
| 2022 | 54 -53.8% YoY -37.9% QoQ | 61 -19.7% YoY 13.0% QoQ | 54 58.8% YoY -11.5% QoQ | 18 -79.3% YoY -66.7% QoQ |
| 2023 | 39 -27.8% YoY 116.7% QoQ | 89 45.9% YoY 128.2% QoQ | 18 -66.7% YoY -79.8% QoQ | 186 933.3% YoY 933.3% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of Nuvectis Pharma stock was 5.3 per week. The last year interest of Nuvectis Pharma stock compared to the last 5 years has changed by 13.21%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -7.41%.
There is not enough data for Nuvectis Pharma news to provide analysis
There is not enough data for Nuvectis Pharma news to provide correlation calculation
There is not enough data for Nuvectis Pharma news to provide analysis